JP2023178487A - Joint function improvement agent - Google Patents
Joint function improvement agent Download PDFInfo
- Publication number
- JP2023178487A JP2023178487A JP2023184382A JP2023184382A JP2023178487A JP 2023178487 A JP2023178487 A JP 2023178487A JP 2023184382 A JP2023184382 A JP 2023184382A JP 2023184382 A JP2023184382 A JP 2023184382A JP 2023178487 A JP2023178487 A JP 2023178487A
- Authority
- JP
- Japan
- Prior art keywords
- present
- joint function
- glucosamine
- vitamin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008407 joint function Effects 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 64
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 46
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960002442 glucosamine Drugs 0.000 claims abstract description 46
- 239000004480 active ingredient Substances 0.000 claims abstract description 28
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 abstract description 32
- 239000000463 material Substances 0.000 abstract description 29
- 210000000845 cartilage Anatomy 0.000 abstract description 20
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 15
- 235000008397 ginger Nutrition 0.000 abstract description 15
- 235000007164 Oryza sativa Nutrition 0.000 abstract description 14
- 244000046146 Pueraria lobata Species 0.000 abstract description 14
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 14
- 235000009566 rice Nutrition 0.000 abstract description 14
- 239000004615 ingredient Substances 0.000 abstract description 12
- 241000988895 Aristotelia chilensis Species 0.000 abstract description 9
- 240000005979 Hordeum vulgare Species 0.000 abstract description 9
- 235000007340 Hordeum vulgare Nutrition 0.000 abstract description 9
- 244000273928 Zingiber officinale Species 0.000 abstract description 9
- 208000006820 Arthralgia Diseases 0.000 abstract description 8
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 241000244268 Peucedanum japonicum Species 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 21
- 210000001612 chondrocyte Anatomy 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 102100030416 Stromelysin-1 Human genes 0.000 description 19
- 229940088594 vitamin Drugs 0.000 description 19
- 229930003231 vitamin Natural products 0.000 description 19
- 235000013343 vitamin Nutrition 0.000 description 19
- 239000011782 vitamin Substances 0.000 description 19
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 241000209094 Oryza Species 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 description 13
- 239000011707 mineral Substances 0.000 description 13
- 239000011575 calcium Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000016611 Proteoglycans Human genes 0.000 description 11
- 108010067787 Proteoglycans Proteins 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 11
- 239000008187 granular material Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- 235000013930 proline Nutrition 0.000 description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 7
- 241000234314 Zingiber Species 0.000 description 7
- 239000013538 functional additive Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 229910052711 selenium Inorganic materials 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 235000011649 selenium Nutrition 0.000 description 7
- -1 sucrose fatty acid ester Chemical class 0.000 description 7
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000001841 zingiber officinale Substances 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 5
- 108010041390 Collagen Type II Proteins 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 229960003438 aspartame Drugs 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 5
- 239000008116 calcium stearate Substances 0.000 description 5
- 235000013539 calcium stearate Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000014705 isoleucine Nutrition 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 235000005772 leucine Nutrition 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 4
- 241000583531 Alpinia purpurata Species 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 229930003448 Vitamin K Natural products 0.000 description 4
- 229960001570 ademetionine Drugs 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229940074393 chlorogenic acid Drugs 0.000 description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 4
- 229940068459 sodium pantothenate Drugs 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000014393 valine Nutrition 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- 235000019168 vitamin K Nutrition 0.000 description 4
- 239000011712 vitamin K Substances 0.000 description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- 229940046010 vitamin k Drugs 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101710108790 Stromelysin-1 Proteins 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 235000008729 phenylalanine Nutrition 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 1
- 240000008554 Aloysia triphylla Species 0.000 description 1
- 235000013668 Aloysia triphylla Nutrition 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 244000062245 Hedychium flavescens Species 0.000 description 1
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 208000024764 elbow pain Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940091186 glucosamine hydrochloride 1500 mg Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940079464 niacin 50 mg Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940011650 valine 25 mg Drugs 0.000 description 1
- 229940104757 vitamin E 50 mg Drugs 0.000 description 1
- 229940047044 vitamin b 12 5 mg Drugs 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Abstract
Description
本発明は、関節機能を改善することが可能な組成物に係り、詳しくは、グルコサミン及び特定の他の成分を有効成分とする組成物に関する。 The present invention relates to a composition capable of improving joint function, and more particularly to a composition containing glucosamine and certain other ingredients as active ingredients.
高齢化が進むにつれて、膝や肘の痛みのような関節痛に悩まされる人口が増加しつつあり、このような関節痛を和らげる医薬品等が望まれている。関節痛の要因の１つである関節炎の改善に効果を有する素材としては、例えば、グルコサミン等のアミノ糖が注目されている（特許文献１参照）。 As the population ages, the number of people suffering from joint pain such as knee and elbow pain is increasing, and there is a desire for pharmaceuticals and the like that can relieve such joint pain. For example, amino sugars such as glucosamine are attracting attention as materials that are effective in improving arthritis, which is one of the causes of joint pain (see Patent Document 1).
本発明の課題は、軟骨を保護して、関節機能を改善することが可能な組成物を提供することにある。 An object of the present invention is to provide a composition that can protect cartilage and improve joint function.
本発明者らは、関節機能を改善すべく、関節部分に存在する軟骨に関し鋭意調査・研究したところ、グルコサミンと特定の他の成分とを組み合わせることにより、高い軟骨保護効果が得られることを見いだし、本発明を完成するに至った。すなわち、グルコサミンと、軟骨保護能がほとんどないか、その能力が小さい特定の他の成分を組み合わせることにより、軟骨をより有効に保護することができることを見いだした。 In order to improve joint function, the present inventors conducted intensive investigation and research into the cartilage present in joints, and discovered that a combination of glucosamine and certain other components can provide a high cartilage protection effect. , we have completed the present invention. That is, the inventors have discovered that cartilage can be more effectively protected by combining glucosamine with certain other components that have little or no chondroprotective ability.
すなわち、本発明は、グルコサミンと、下記（ａ）～（ｆ）からなる群より選ばれる少なくとも１種の成分とを有効成分として含有することを特徴とする組成物に関する。
（ａ）大麦、長命草、葛、稲、マキベリー、及びショウガから選ばれる少なくとも１種の植物素材
（ｂ）アスパルテーム、ショ糖脂肪酸エステル、及びステアリン酸カルシウムから選ばれる少なくとも１種の機能性添加剤
（ｃ）アラニン、アスパラギン、グルタミン酸、ヒスチジン、イソロイシン、ロイシン、フェニルアラニン、プロリン、セリン、チロシン、バリン、及びＳ－アデノシルメチオニンから選ばれる少なくとも１種のアミノ酸
（ｄ）没食子酸、及びクロロゲン酸から選ばれる少なくとも１種のポリフェノール
（ｅ）ビタミンＡ、ビタミンＢ１、ビタミンＢ２、ビタミンＢ１２、ビタミンＣ、ビタミンＤ３、パントテン酸ナトリウム、ナイアシン、ビオチン、ビタミンＫ、β－カロテン、カルシウム及びセレンから選ばれる少なくとも１種のビタミン・ミネラル類
（ｆ）プロテオグリカン、及びII型コラーゲンから選ばれる少なくとも１種の軟骨成分
That is, the present invention relates to a composition containing glucosamine and at least one component selected from the group consisting of (a) to (f) below as active ingredients.
(a) At least one plant material selected from barley, Chomeiso, Kudzu, rice, Maqui berry, and ginger (b) At least one functional additive selected from aspartame, sucrose fatty acid ester, and calcium stearate ( c) At least one amino acid selected from alanine, asparagine, glutamic acid, histidine, isoleucine, leucine, phenylalanine, proline, serine, tyrosine, valine, and S-adenosylmethionine (d) selected from gallic acid and chlorogenic acid At least one type of polyphenol (e) At least one type selected from vitamin A, vitamin B1, vitamin B2, vitamin B12, vitamin C, vitamin D3, sodium pantothenate, niacin, biotin, vitamin K, β-carotene, calcium, and selenium. (f) At least one cartilage component selected from proteoglycans and type II collagen.
本発明の組成物は、軟骨の保護作用を有する関節機能改善剤として用いることができる。 The composition of the present invention can be used as a joint function improving agent that has a cartilage protective effect.
本発明の組成物は、グルコサミンと（ａ）～（ｆ）からなる群より選ばれる少なくとも１種の成分とからなる有効成分を添加して得たものであってもよい。 The composition of the present invention may be obtained by adding an active ingredient consisting of glucosamine and at least one ingredient selected from the group consisting of (a) to (f).
また、本発明の組成物は、経口用であることが好ましく、錠剤、カプセル剤、粉末剤、顆粒剤、又は液剤であることが好ましい。 Further, the composition of the present invention is preferably for oral use, and is preferably in the form of a tablet, capsule, powder, granule, or liquid.
また、本発明は、上記本発明の組成物を摂取させることを特徴とする関節機能改善方法（ただし、医療行為を除く）に関する。 The present invention also relates to a method for improving joint function (excluding medical treatment), which comprises ingesting the composition of the present invention.
本発明の組成物によれば、軟骨を保護して、関節機能を改善することができる。 According to the composition of the present invention, cartilage can be protected and joint function can be improved.
本発明の組成物は、グルコサミンと、下記（ａ）～（ｆ）からなる群より選ばれる少なくとも１種の成分（以下、他成分ということがある）とを有効成分として含有することを特徴とする。グルコサミンと共に用いられる下記（ａ）～（ｆ）の成分は、１種単独（例えば（ａ）成分）で用いてもよいし、２種以上組み合わせて用いてもよい。他成分を２種以上組み合せて用いる場合、グルコサミンと相乗効果の高い他成分同士を組み合わせることが好ましい。 The composition of the present invention is characterized by containing glucosamine and at least one component selected from the group consisting of (a) to (f) below (hereinafter sometimes referred to as other components) as active ingredients. do. The following components (a) to (f) used together with glucosamine may be used alone (for example, component (a)) or in combination of two or more. When using a combination of two or more other ingredients, it is preferable to combine other ingredients that have a high synergistic effect with glucosamine.
本発明の組成物（関節機能改善組成物）は、軟骨細胞の破壊を抑制することにより軟骨を保護して、より有効に関節の痛みを改善（予防を含む）することができ、関節機能を十分に発揮できるようになることから、関節機能改善剤として用いることができる。また、本発明の関節機能改善組成物は、全身の軟骨を保護して、全身の関節の痛みを改善することができるが、特に腰、股関節、膝関節の軟骨を保護し、かかる箇所の痛みを改善することができ、これにより関節機能を改善できる。 The composition of the present invention (composition for improving joint function) can protect cartilage by suppressing the destruction of chondrocytes, improve joint pain more effectively (including prevention), and improve joint function. It can be used as a joint function improving agent because it can be used to its full potential. Furthermore, the composition for improving joint function of the present invention can protect cartilage throughout the body and improve joint pain throughout the body, but it can particularly protect cartilage in the lower back, hip joints, and knee joints, thereby improving pain in such areas. This can improve joint function.
［グルコサミン］
本発明のグルコサミンとしては、グルコサミン及びその塩、Ｎ－アセチルグルコサミンを用いることができる。塩としては、塩酸塩、硫酸塩、リン酸塩等を挙げることができる。かかるグルコサミンは、生物由来のものであってもよく、化学合成されたものであってもよい。
[Glucosamine]
As the glucosamine of the present invention, glucosamine and its salts, and N-acetylglucosamine can be used. Examples of the salt include hydrochloride, sulfate, phosphate and the like. Such glucosamine may be of biological origin or may be chemically synthesized.
［他成分］
（ａ）植物素材
本発明の関節機能改善組成物においては、グルコサミンと共に、有効成分として、大麦、長命草、葛、稲、マキベリー、及びショウガから選ばれる少なくとも１種の植物素材を用いることが好ましい。
[Other ingredients]
(a) Plant material In the joint function improving composition of the present invention, it is preferable to use at least one plant material selected from barley, chomeiso, kudzu, rice, maqui berry, and ginger as an active ingredient together with glucosamine. .
これらの植物素材は、葉、茎、根、花、実、幹、枝等、植物のいずれの部位であってもよく、植物素材そのもの（乾燥物を含む）の他、その粉砕物、搾汁、抽出物等の植物素材処理物を用いることができる。粉砕物としては、粉末、顆粒等が挙げられる。搾汁や抽出物は、液状であってもよいが、ペースト状や乾燥粉末として用いることもできる。抽出物は、適当な溶媒を用いて抽出することにより得ることができ、溶媒としては、例えば、水（熱水）、エタノール、含水エタノールを用いることができる。これらの植物素材は、市販されているものを使用することができる。 These plant materials may be any part of the plant, such as leaves, stems, roots, flowers, fruits, trunks, branches, etc., and may include the plant materials themselves (including dried materials), crushed products, and squeezed juice. , extracts, and other processed plant materials can be used. Examples of the pulverized product include powder, granules, and the like. The squeezed juice or extract may be in liquid form, but it can also be used in the form of a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water (hot water), ethanol, and aqueous ethanol. Commercially available plant materials can be used as these plant materials.
大麦としては、二条大麦、六条大麦等を用いることができる。本発明の植物素材として用いる部位としては、茎、葉が好ましく、特に若葉が好ましい。 As the barley, two-row barley, six-row barley, etc. can be used. The parts used as the plant material of the present invention are preferably stems and leaves, with young leaves being particularly preferred.
長命草は、セリ科カワラボウフウ属に属するボタンボウフウとも呼ばれる多年草植物である。本発明の植物素材として用いる部位としては、葉、根が好ましい。 Chomeiso is a perennial plant also called Botanbofuu that belongs to the Apiaceae family. The parts used as the plant material of the present invention are preferably leaves and roots.
葛は、マメ科クズ属のつる性の多年草植物である。本発明の植物素材として用いる部位としては、花、根が好ましく、花が特に好ましい。葛花としては、蕾から全開した花までのいずれの過程で採取したものを用いてもよく、各過程で採取したものを混合して用いることもできる。葛の種類としては、特に制限はないが、プエラリア・トムソニイ（Pueraria thomsonii）、プエラリア・ロバータ（Pueraria lobata）、プエラリア・スンバーギアナ（Pueraria thunbergiana）等を例示することができる。 Kudzu is a climbing perennial plant belonging to the Fabaceae family and the genus Kudzu. The parts used as the plant material of the present invention are preferably flowers and roots, and flowers are particularly preferred. Kudzu flowers may be collected at any stage from buds to fully opened flowers, or a mixture of kudzu flowers collected at each stage may be used. The type of kudzu is not particularly limited, but examples include Pueraria thomsonii, Pueraria lobata, and Pueraria thunbergiana.
稲は、イネ科イネ属の植物である。本発明の植物素材として用いる部位としては、玄米の外皮や胚が好ましく、具体的には、玄米を精白する際に副産物として得られる米ぬかを用いることが好ましい。稲の種類としては、特に制限はなく、ジャポニカ種、インディカ種等を挙げることができる。 Rice is a plant belonging to the Poaceae family, Poaceae. The parts used as the plant material of the present invention are preferably brown rice rinds and embryos, and specifically, it is preferable to use rice bran obtained as a by-product when milling brown rice. There are no particular restrictions on the type of rice, and examples include japonica and indica.
マキベリーは、チリのパタゴニアを原産地とするポルトノキ科の植物であり、学術名は、Aristotellia chilensisである。本発明の植物素材として用いる部位としては、果実が好ましい。 Maqui berry is a plant of the Portonaceae family that is native to Patagonia, Chile, and its scientific name is Aristotelia chilensis. The part used as the plant material of the present invention is preferably a fruit.
ショウガは、ショウガ科ショウガ属の植物であり、例えば、学名がZingiber officinaleである三州生姜、黄生姜を挙げることができる。また、インドネシアやインドで栽培されている学名がZingiber officinale var. Rubraである赤ショウガ（現地名はJahe merah）も好ましく用いることができる。本発明の植物素材として用いる部位としては、根茎が好ましい。 Ginger is a plant belonging to the Zingiberaceae family and genus Zingiber, and includes, for example, Sanshu ginger and Yellow ginger whose scientific name is Zingiber officinale. Furthermore, red ginger (local name: Jahe merah), whose scientific name is Zingiber officinale var. Rubra and which is cultivated in Indonesia and India, can also be preferably used. As the part used as the plant material of the present invention, rhizomes are preferable.
（ｂ）機能性添加剤
本発明の関節機能改善組成物においては、グルコサミンと共に、有効成分として、アスパルテーム、ショ糖脂肪酸エステル、及びステアリン酸カルシウムから選ばれる少なくとも１種の機能性添加剤を用いることが好ましい。アスパルテームは甘味料等として、ショ糖脂肪酸エステルやステアリン酸カルシウムは滑沢剤等として用いることができる。
(b) Functional additive In the joint function improving composition of the present invention, at least one functional additive selected from aspartame, sucrose fatty acid ester, and calcium stearate may be used as an active ingredient together with glucosamine. preferable. Aspartame can be used as a sweetener, and sucrose fatty acid ester and calcium stearate can be used as a lubricant.
（ｃ）アミノ酸
本発明の関節機能改善組成物においては、グルコサミンと共に、有効成分として、アラニン、アスパラギン、グルタミン酸、ヒスチジン、イソロイシン、ロイシン、フェニルアラニン、プロリン、セリン、チロシン、バリン、及びＳ－アデノシルメチオニンから選ばれる少なくとも１種のアミノ酸（塩を含む）を用いることが好ましい。塩としては、例えば、ナトリウム塩、塩酸塩等を挙げることができる。
（ｄ）ポリフェノール
本発明の関節機能改善組成物においては、グルコサミンと共に、有効成分として、没食子酸、及びクロロゲン酸から選ばれる少なくとも１種のポリフェノールを用いることが好ましい。
(c) Amino acids In the joint function improving composition of the present invention, in addition to glucosamine, active ingredients include alanine, asparagine, glutamic acid, histidine, isoleucine, leucine, phenylalanine, proline, serine, tyrosine, valine, and S-adenosylmethionine. It is preferable to use at least one type of amino acid (including salt) selected from the following. Examples of the salt include sodium salt, hydrochloride, and the like.
(d) Polyphenol In the joint function improving composition of the present invention, it is preferable to use at least one polyphenol selected from gallic acid and chlorogenic acid as an active ingredient together with glucosamine.
（ｅ）ビタミン・ミネラル類
本発明の関節機能改善組成物においては、グルコサミンと共に、有効成分として、ビタミンＡ、ビタミンＢ１、ビタミンＢ２、ビタミンＢ１２、ビタミンＣ、ビタミンＤ３、パントテン酸ナトリウム、ナイアシン、ビオチン、ビタミンＫ、β－カロテン、カルシウム及びセレンから選ばれる少なくとも１種のビタミン・ミネラル類を用いることが好ましい。なお、本発明のミネラル類としてのカルシウム、セレンは、これらの金属を含む化合物の形態を含む。
(e) Vitamins and minerals In the joint function improving composition of the present invention, in addition to glucosamine, active ingredients include vitamin A, vitamin B1, vitamin B2, vitamin B12, vitamin C, vitamin D3, sodium pantothenate, niacin, and biotin. It is preferable to use at least one vitamin/mineral selected from , vitamin K, β-carotene, calcium, and selenium. Note that calcium and selenium as minerals of the present invention include forms of compounds containing these metals.
（ｆ）軟骨成分
本発明の関節機能改善組成物においては、グルコサミンと共に、有効成分として、プロテオグリカン、及びII型コラーゲンから選ばれる少なくとも１種の軟骨成分を用いることが好ましい。
(f) Cartilage component In the joint function improving composition of the present invention, it is preferable to use at least one cartilage component selected from proteoglycans and type II collagen as an active ingredient together with glucosamine.
プロテオグリカンは、タンパク質をコアとして、コンドロイチン硫酸やデルマタン硫酸等のグリコサミノグリカンが共有結合した複合多糖であり、動物組織、特に軟骨組織に多く存在する。プロテオグリカンは生体内で、コア蛋白質がさらにヒアルロン酸に結合した構造で存在することも知られており、その分子量は、数万～数千万と大きい。本発明で用いるプロテオグリカンとしては、具体的に、動物由来のプロテオグリカンを挙げることができ、市販品を使用することができる。 Proteoglycans are complex polysaccharides in which glycosaminoglycans such as chondroitin sulfate and dermatan sulfate are covalently bonded to a protein core, and are present in large quantities in animal tissues, especially cartilage tissues. It is also known that proteoglycan exists in a living body in a structure in which a core protein is further bonded to hyaluronic acid, and its molecular weight is large, ranging from tens of thousands to tens of millions of millions. Specific examples of proteoglycans used in the present invention include animal-derived proteoglycans, and commercially available products can be used.
II型コラーゲンは、軟骨に多く含まれるコラーゲンであり、例えば、鶏、豚等の軟骨から抽出したものを用いることができ、市販品を使用することができる。 Type II collagen is collagen that is abundantly contained in cartilage, and for example, collagen extracted from cartilage of chickens, pigs, etc. can be used, and commercially available products can be used.
本発明の関節機能改善組成物は、軟骨の保護作用を有する関節機能改善剤として用いることができ、かかる関節機能改善剤は、グルコサミン及び所定の他成分を含有し、関節機能改善に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではない。例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに関節機能改善効果の機能がある旨を表示したものが本発明の範囲に含まれる。例えば、医薬品（医薬部外品を含む）や、化粧品や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品等を挙げることができる。いわゆる健康食品においては、「膝や腰の悩みに」、「健やかな歩みに」、「軽やかな動きに」、「関節機能を整える」、「関節の動きをなめらかにする」、「関節機能を改善する」、「関節の動きの悩みを緩和する」、「関節の動きを助ける」、「関節の動きをサポートする」等を表示したものを例示することができる。本発明の関節機能改善組成物は、上記の効果が気になる人であれば性別や年齢に関係なく摂取することができるが、本発明の関節機能改善組成物の効果をより有効に享受することができることから、疾病者を除く健常者が摂取することが望ましく、特に上記の悩みをもつ高齢者が摂取することが望ましい。 The joint function improving composition of the present invention can be used as a joint function improving agent having a cartilage protective effect, and the joint function improving agent contains glucosamine and other predetermined components, and is useful for improving joint function. There are no particular restrictions on the product as long as it can be distinguished from other products. For example, the scope of the present invention includes products in which a statement indicating that the product has a function of improving joint function on the main body, packaging, instruction manual, or advertising material of the present invention is included. For example, so-called health foods such as pharmaceuticals (including quasi-drugs), cosmetics, and functional foods whose efficacy has been approved by designated organizations such as foods for specified health uses, foods with nutritional function claims, and foods with functional claims. can be mentioned. So-called health foods include ``for knee and lower back problems'', ``for healthy walking'', ``for light movement'', ``adjusting joint function'', ``smoothing joint movement'', and ``improving joint function''. For example, the words "improve joint movement", "alleviate joint movement problems", "help joint movement", and "support joint movement" are displayed. The joint function improving composition of the present invention can be taken by anyone who is concerned about the above-mentioned effects regardless of gender or age; however, the joint function improving composition of the present invention can be taken more effectively. Therefore, it is desirable for healthy people excluding those with diseases to take it, and it is especially desirable for elderly people who have the above-mentioned problems to take it.
本発明の関節機能改善組成物は、経口用又は外用として使用することができる。外用剤としては、皮膚、頭皮等に塗布して用いるものであれば、特に制限はなく、その形態としては、軟膏剤、クリーム剤、ジェル剤、ローション剤、乳液剤、パック剤、湿布剤等の皮膚外用剤や、注射剤等の形態を挙げることができる。 The joint function improving composition of the present invention can be used orally or externally. External preparations are not particularly limited as long as they are applied to the skin, scalp, etc., and their forms include ointments, creams, gels, lotions, emulsions, packs, poultices, etc. Forms such as external skin preparations and injections can be mentioned.
また、本発明の関節機能改善組成物を経口剤として用いる場合、その形態としては、例えば、錠剤、カプセル剤、粉末剤、顆粒剤、液剤、粒状剤、棒状剤、板状剤、ブロック状剤、固形状剤、丸状剤、ペースト状剤、クリーム状剤、カプレット状剤、ゲル状剤、チュアブル状剤、スティック状剤等を挙げることができる。これらの中でも、錠剤、カプセル剤、粉末剤、顆粒剤、液剤の形態が特に好ましい。具体的には、サプリメントや、ペットボトル、缶、瓶等に充填された容器詰飲料や、水（湯）、牛乳、果汁、青汁等に溶解して飲むためのインスタント粉末飲料、インスタント顆粒飲料を例示することができる。これらは食事の際などに手軽に飲用しやすく、また嗜好性を高めることができるという点で好ましい。 In addition, when the joint function improving composition of the present invention is used as an oral preparation, the forms include, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, and blocks. , solid preparations, pills, paste preparations, cream preparations, caplet preparations, gel preparations, chewable preparations, stick preparations, and the like. Among these, tablet, capsule, powder, granule, and liquid forms are particularly preferred. Specifically, supplements, packaged beverages filled in plastic bottles, cans, bottles, etc., instant powdered beverages and instant granular beverages that can be dissolved in water (hot water), milk, fruit juice, green juice, etc. can be exemplified. These are preferable because they are easy to drink during meals and can enhance palatability.
本発明の関節機能改善組成物におけるグルコサミン及び他成分（有効成分）の含有量としては、その効果の奏する範囲で適宜含有させればよい。 The content of glucosamine and other ingredients (active ingredients) in the joint function improving composition of the present invention may be appropriately contained within the range where their effects are achieved.
一般的には、本発明の関節機能改善組成物が医薬品やサプリメント（錠剤，カプセル剤）の場合には、有効成分が乾燥質量換算で全体の０．０１～１００質量％含まれていることが好ましく、０．１～８５質量％含まれていることがより好ましく、０．５～７０質量％含まれていることがさらに好ましい。 Generally, when the joint function improving composition of the present invention is a drug or a supplement (tablet, capsule), the active ingredient may be contained in an amount of 0.01 to 100% by mass on a dry mass basis. The content is preferably 0.1 to 85% by mass, more preferably 0.5 to 70% by mass.
本発明の関節機能改善組成物が容器詰飲料（液剤）である場合には、有効成分が乾燥質量換算で全体の０．０１～１５質量％含まれていることが好ましく、０．０３～１２．５質量％含まれていることがより好ましく、０．０５～１０質量％含まれていることがさらに好ましい。 When the joint function improving composition of the present invention is a packaged beverage (liquid), it is preferable that the active ingredient is contained in an amount of 0.01 to 15% by mass, and preferably 0.03 to 12% by mass of the total in terms of dry mass. The content is more preferably .5% by mass, and even more preferably 0.05 to 10% by mass.
また、本発明の関節機能改善組成物がインスタント粉末飲料（粉末剤）、インスタント顆粒飲料（顆粒剤）である場合には、有効成分が乾燥質量換算で全体の０．１～８０質量％含まれていることが好ましく、０．５～７０質量％含まれていることがより好ましく、１～６０質量％含まれていることがさらに好ましい。 In addition, when the joint function improving composition of the present invention is an instant powder drink (powder) or instant granule drink (granules), the active ingredient is contained in an amount of 0.1 to 80% by mass of the total in terms of dry mass. The content is preferably 0.5 to 70% by mass, more preferably 1 to 60% by mass.
本発明の効果をより有効に発揮させるためには、有効成分が乾燥質量換算で本発明の関節機能改善組成物全体（水分を除く）の８０質量％以上含まれていることが好ましく、９０質量％以上含まれていることがより好ましく、９５質量％以上含まれていることがさらに好ましく、１００質量％であることが特に好ましい。さらに、本発明の関節機能改善組成物が成分（ａ）～（ｆ）のいずれかを含有する場合、その含有される成分は、本発明における有効成分のみで構成されることが好ましい。すなわち、本発明の関節機能改善組成物が例えば成分（ａ）（植物素材）を含む場合には、大麦、長命草、葛、稲、マキベリー、ショウガ以外の植物素材を含まないように構成することが好ましい。 In order to more effectively exhibit the effects of the present invention, it is preferable that the active ingredient is contained in an amount of 80% by mass or more of the entire joint function improving composition of the present invention (excluding water) in terms of dry mass, and 90% by mass. % or more, more preferably 95% by mass or more, and particularly preferably 100% by mass. Furthermore, when the joint function improving composition of the present invention contains any of the components (a) to (f), it is preferable that the contained components consist only of the active ingredients of the present invention. That is, when the joint function improving composition of the present invention contains component (a) (plant material), for example, it should be configured so that it does not contain plant materials other than barley, chomeiso, kudzu, rice, maqui berry, and ginger. is preferred.
本発明の関節機能改善組成物の摂取量としては特に制限はないが、本発明の効果をより顕著に発揮させる観点から、１日当たりの有効成分の摂取量が、５００ｍｇ／日以上となるように摂取することが好ましく、８００ｍｇ／日以上となるように摂取することがより好ましく、１０００ｍｇ／日以上となるように摂取することがさらに好ましい。その上限は特に制限されないが、例えば、５ｇ／日であり、好ましくは４ｇ／日である。なお、グルコサミン塩酸塩の一日の摂取量は、５００～４０００ｍｇ／日となるように摂取することが好ましく、１０００～３０００ｍｇ／日となるように摂取することがより好ましく、１５００～２５００ｍｇ／日となるように摂取することがさらに好ましく、１８５０～２２５０ｍｇ／日となるように摂取することが特に好ましい。 There is no particular limit to the intake amount of the joint function improving composition of the present invention, but from the viewpoint of exhibiting the effects of the present invention more markedly, the intake amount of the active ingredient per day should be 500 mg/day or more. It is preferable to ingest it, more preferably at least 800 mg/day, even more preferably at least 1000 mg/day. The upper limit is not particularly limited, but is, for example, 5 g/day, preferably 4 g/day. The daily intake of glucosamine hydrochloride is preferably 500 to 4000 mg/day, more preferably 1000 to 3000 mg/day, and 1500 to 2500 mg/day. It is more preferable to take in an amount of 1,850 to 2,250 mg/day, and it is particularly preferable to take an amount of 1,850 to 2,250 mg/day.
本発明の関節機能改善組成物は、1日の摂取量が前記摂取量となるように、１つの容器に、又は例えば２～３の複数の容器に分けて、1日分として収容することができる。 The joint function improving composition of the present invention can be stored in one container or divided into, for example, 2 to 3 containers, so that the daily intake amount is the above-mentioned intake amount. can.
グルコサミン及び他成分の配合質量比としては、乾燥質量換算で、０．５：１～７０：１の範囲であることが好ましく、０．７５：１～６０：１の範囲であることがより好ましく、１：１～６０：１の範囲であることがさらに好ましく、１：１～５０：１の範囲であることが特に好ましい。グルコサミン及び他成分の配合比が、上記範囲であることにより、本発明の効果をより有効に発揮することができる。 The blending mass ratio of glucosamine and other components is preferably in the range of 0.5:1 to 70:1, more preferably in the range of 0.75:1 to 60:1, in terms of dry mass. , more preferably in the range of 1:1 to 60:1, particularly preferably in the range of 1:1 to 50:1. When the blending ratio of glucosamine and other components is within the above range, the effects of the present invention can be more effectively exhibited.
本発明の関節機能改善組成物は、必要に応じて、経口剤又は外用剤として許容される有効成分以外の成分を添加して、公知の方法によって製造することができる。 The joint function improving composition of the present invention can be produced by a known method by adding ingredients other than the active ingredients that are acceptable as oral or external preparations, if necessary.
また、本発明の経口剤としての関節機能改善組成物としては、有効成分を含有する関節機能改善組成物の他、食品に対して有効成分を添加して得た関節機能改善組成物（関節機能改善食品）を挙げることができ、例えば、通常の食品（天然の食品を含む）に比して本発明の有効成分含有量を増加させた食品や、本発明の有効成分を通常含まない食品に対して有効成分を添加した食品を挙げることができる。有効成分の添加は、それぞれの成分を別々に添加してもよいし、同時に添加してもよく、また、有効成分以外の他の成分と共に添加してもよい。 In addition, as the joint function improving composition as an oral preparation of the present invention, in addition to joint function improving compositions containing active ingredients, joint function improving compositions obtained by adding active ingredients to foods (joint function improving compositions) include joint function improving compositions containing active ingredients. For example, foods with increased content of the active ingredient of the present invention compared to normal foods (including natural foods), and foods that do not normally contain the active ingredient of the present invention. On the other hand, foods containing active ingredients can be mentioned. The active ingredients may be added separately, simultaneously, or together with other ingredients other than the active ingredients.
本発明の関節機能改善食品としては、例えば、炭酸飲料、栄養飲料、果実飲料、乳酸飲料、スムージー、青汁等の飲料；アイスクリーム、アイスシャーベット、かき氷等の冷菓；そば、うどん、はるさめ、中華麺、即席麺等の麺類；飴、キャンディー、ガム、チョコレート、錠菓、スナック菓子、ビスケット、ゼリー、ジャム、クリーム、焼き菓子、パン等の菓子類；かまぼこ、ハム、ソーセージ等の水産・畜産加工食品；加工乳、発酵乳、ヨーグルト等の乳製品；サラダ油、てんぷら油、マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及びその加工食品；ソース、醤油等の調味料；カレー、シチュー、親子丼、お粥、雑炊、中華丼、かつ丼、天丼、牛丼、ハヤシライス、オムライス、おでん、マーボドーフ、餃子、シューマイ、ハンバーグ、ミートボール、各種ソース、各種スープ等のレトルトパウチ食品などを挙げることができる。 Examples of the joint function improving food of the present invention include drinks such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; frozen desserts such as ice cream, ice sorbet, and shaved ice; Noodles such as noodles and instant noodles; Confectionery such as candy, candies, gum, chocolate, tablets, snack foods, biscuits, jellies, jams, creams, baked goods, and bread; Fishery and livestock processed foods such as kamaboko, ham, and sausages. ; Dairy products such as processed milk, fermented milk, and yogurt; Oils and fats and processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing; Seasonings such as sauces and soy sauce; Curry, stew, and oyakodon Examples include retort pouch foods such as porridge, porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hashed rice, omelet rice, oden, marbodoff, gyoza, shumai, hamburger steak, meatballs, various sauces, and various soups. .
本発明の関節機能改善方法としては、上記説明した本発明の関節機能改善組成物を摂取させることを特徴とするが、医療行為は含まれない。本発明の関節機能改善組成物は疾病者を除く健常者が摂取させることが望ましく、特に上記の悩みをもつ高齢者に摂取させることが望ましい。本発明の方法としては、例えば、レストラン等の飲食店において、本発明の関節機能改善食品を提供することにより、関節機能改善効果を得る方法を挙げることができる。 The joint function improving method of the present invention is characterized by ingesting the above-described joint function improving composition of the present invention, but does not include medical treatment. The joint function-improving composition of the present invention is preferably ingested by healthy people excluding diseased people, and particularly preferably by elderly people who have the above-mentioned problems. Examples of the method of the present invention include a method of obtaining a joint function improving effect by providing the joint function improving food of the present invention in a restaurant or other eatery.
以下、本発明を実施例に基づき説明する。
［実施例１］
（１）軟骨細胞（ＮＨＡｃ－ｋｎ）を５×１０４ｃｅｌｌｓ／ｍＬとなるよう１０％ＦＢＳ－ＤＭＥＭにて調製し、それを２００μＬずつ９６ ｗｅｌｌ ｐｌａｔｅへ播種し、最終的に１×１０４ｃｅｌｌｓ／ｗｅｌｌとなるように調整した。
（２）１～２日間前培養後、下記のようにサンプル添加を行った。各サンプルは目的の終濃度の４倍にて濃度調整を行った。
Hereinafter, the present invention will be explained based on examples.
[Example 1]
(1) Chondrocytes (NHAc-kn) were prepared in 10% FBS-DMEM to a concentration of 5×10 4 cells/mL, and 200 μL of each was seeded onto a 96-well plate, resulting in a final concentration of 1×10 4 cells. /well.
(2) After preculture for 1 to 2 days, samples were added as described below. The concentration of each sample was adjusted to 4 times the desired final concentration.
なお、水に不溶のサンプル（他成分）に関してはＤＭＳＯにて溶解した後、４倍濃度サンプル ｉｎ １％ＤＭＳＯ－１０％ＦＢＳ－ＤＭＥＭとなるよう調整した。塩化カルシウム以外のＣａサンプルは１Ｎ ＨＣｌに溶解した後、４倍濃度サンプル ｉｎ １／５０Ｎ ＨＣｌ－１０％ＦＢＳ－ＤＭＥＭとなるよう調整した。ＩＬ１ｂ溶液は、１０％ＦＢＳ－ＤＭＥＭ１５ｍＬに対して１０μｇ／ｍＬ ＩＬ１ｂを２μＬの割合で調整した。なお、グルコサミンとしては、市販のグルコサミン塩酸塩を用いた。 Note that samples insoluble in water (other components) were dissolved in DMSO and then adjusted to a 4-fold concentration sample in 1% DMSO-10% FBS-DMEM. Ca samples other than calcium chloride were dissolved in 1N HCl and then adjusted to a 4-fold concentration sample in 1/50N HCl-10% FBS-DMEM. The IL1b solution was prepared at a ratio of 2 μL of 10 μg/mL IL1b to 15 mL of 10% FBS-DMEM. In addition, as glucosamine, commercially available glucosamine hydrochloride was used.
（３）サンプル添加より約１８時間後、ＣｅｌｌＡｍｐ Ｄｉｒｅｃｔ ＲＮＡ Ｐｒｅｐ Ｋｉｔ ｆｏｒ ＲＴ－ＰＣＲ（Ｔａｋａｒａ）にて細胞を回収した。その後、Ｏｎｅ Ｓｔｅｐ ＳＹＢＲ（登録商標）ＰｒｉｍｅＳｃｒｉｐｔＴＭ ＲＴ－ＰＣＲ Ｋｉｔ ＩＩを用いてＭＭＰ３の発現量を測定した。なお、内部標準としてＲＰＬＰ０の測定も行った。なお、ＭＭＰ-３発現量が高い場合は、関節軟骨細胞の破壊が進行していることを示し、ＭＭＰ-３発現量が低い場合は、関節軟骨細胞の破壊が抑制され、関節軟骨細胞が保護されていると解される。 (3) Approximately 18 hours after sample addition, cells were collected using CellAmp Direct RNA Prep Kit for RT-PCR (Takara). Thereafter, the expression level of MMP3 was measured using One Step SYBR (registered trademark) PrimeScript ™ RT-PCR Kit II. Note that RPLP0 was also measured as an internal standard. In addition, when the expression level of MMP-3 is high, it indicates that the destruction of articular chondrocytes is progressing, and when the expression level of MMP-3 is low, the destruction of articular chondrocytes is suppressed, and the articular chondrocytes are protected. It is understood that
その結果を表４～表１０、及び図１～図１３に示す。 The results are shown in Tables 4 to 10 and FIGS. 1 to 13.
各図は、左から、「コントロール」、「ＩＬ１b添加」、「（ＩＬ１b添加に対する）グルコサミンの単独添加」、「（ＩＬ１b添加に対する）他成分の単独添加」、「（ＩＬ１b添加に対する）グルコサミン＋他成分添加」の結果を表す。また、グラフ下部の説明における数値は、サンプル濃度を示し、例えば、図１の左上のグラフの「Ｇ_１００」は、グルコサミン１００（μｇ／ｍＬ）を示す。添加成分の濃度単位は、すべてのグラフにおいて、μｇ／ｍＬである。 Each figure shows, from left to right, "control", "IL1b addition", "single addition of glucosamine (to IL1b addition)", "single addition of other components (to IL1b addition)", "glucosamine + other (to IL1b addition)" Component addition” results are shown. Further, the numerical value in the explanation at the bottom of the graph indicates the sample concentration; for example, "G_100" in the upper left graph of FIG. 1 indicates glucosamine 100 (μg/mL). The concentration unit of added components is μg/mL in all graphs.
大麦については、若葉の乾燥粉砕末を用いた。
長命草については、生葉の微粉砕末を用いた。
葛については、花の熱水抽出物（乾燥粉末）を用いた。
米ぬかについては、市販品を用いた。
マキベリーについては、市販品の果実の乾燥粉末を用いた。
赤ショウガ（Zingiber officinale var. Rubra）については、根茎の熱水抽出物（乾燥粉末）を用いた。
ショウガ（Zingiber officinale）については、根茎の熱水抽出物（乾燥粉末）を用いた。
レモンバーベナについては、葉の乾燥粉砕末を用いた。
For barley, dry and ground powder of young leaves was used.
For Chomeisou, a finely ground powder of fresh leaves was used.
For kudzu, a hot water extract (dry powder) of the flower was used.
As for rice bran, a commercially available product was used.
For Maqui berry, a commercially available dried fruit powder was used.
For red ginger (Zingiber officinale var. Rubra), a hot water extract (dry powder) of the rhizome was used.
For ginger (Zingiber officinale), a hot water extract (dry powder) of the rhizome was used.
For lemon verbena, dried and crushed leaf powder was used.
表４～表１０、及び図１～図１３に示すように、グルコサミンと、本発明の特定の他成分を組み合わせることにより、ＭＭＰ-３発現量が相乗的に低下した。したがって、本発明の関節機能改善組成物によれば、炎症が抑えられるとともに、関節軟骨細胞を保護（関節軟骨細胞の破壊を抑制）し、より効果的に関節の痛みを改善することができる。 As shown in Tables 4 to 10 and FIGS. 1 to 13, the combination of glucosamine and specific other components of the present invention synergistically reduced the expression level of MMP-3. Therefore, according to the joint function improving composition of the present invention, inflammation can be suppressed, and articular chondrocytes can be protected (destruction of articular chondrocytes can be suppressed), thereby making it possible to more effectively improve joint pain.
［実施例２］（錠剤の製造）
下記成分からなるタブレット（６粒で３０００ｍｇ）を製造した。
[Example 2] (Manufacture of tablets)
Tablets (6 tablets, 3000 mg) were produced containing the following ingredients.
グルコサミン塩酸塩 ２０００ｍｇ
プロテオグリカン ５ｍｇ
化石サンゴＣａ １５０ｍｇ
ステアリン酸カルシウム ５０ｍｇ
β－カロテン １０ｍｇ
ビタミンＢ１ ５ｍｇ
ビタミンＢ２ ５ｍｇ
ビタミンＢ１２ ５ｍｇ
ビタミンＤ３ ２．５ｍｇ
長命草末 ３００ｍｇ
プロリン ３０ｍｇ
結晶セルロース ５０ｍｇ
ショ糖脂肪酸エステル ３０ｍｇ
麦芽糖 残部
Glucosamine hydrochloride 2000mg
Proteoglycan 5mg
Fossil coral Ca 150mg
Calcium stearate 50mg
β-carotene 10mg
Vitamin B1 5mg
Vitamin B2 5mg
Vitamin B12 5mg
Vitamin D3 2.5mg
Chomeisou end 300mg
Proline 30mg
Crystalline cellulose 50mg
Sucrose fatty acid ester 30mg
maltose remainder
上記錠剤は６粒を一日に２～３回に分けて、噛み砕いて服用するか、又は水と共に噛まずに服用する。 The above tablets are taken in 6 tablets divided into 2 to 3 times a day and chewed, or taken without chewing with water.
［実施例３］（カプセル剤の製造）
下記混合物をソフトカプセルに封入し、カプセル剤６粒を製造した。
[Example 3] (Manufacture of capsules)
The following mixture was encapsulated in soft capsules to produce 6 capsules.
グルコサミン塩酸塩 １５００ｍｇ
プロテオグリカン ５ｍｇ
米ぬか抽出物 ２０ｍｇ
マキベリー末 １００ｍｇ
貝殻焼成Ｃａ １２０ｍｇ
ビタミンＥ ３０ｍｇ
ナイアシン ５ｍｇ
クロロゲン酸 １０ｍｇ
プロリン ２０ｍｇ
セレン ５ｍｇ
パントテン酸ナトリウ １０ｍｇ
麦芽糖 残部
Glucosamine hydrochloride 1500mg
Proteoglycan 5mg
Rice bran extract 20mg
Maqui berry powder 100mg
Shell fired Ca 120mg
Vitamin E 30mg
Niacin 5mg
Chlorogenic acid 10mg
Proline 20mg
Selenium 5mg
Sodium pantothenate 10mg
maltose remainder
上記錠剤は６粒を一日に２～３回に分けて、水と共に服用する。 The above tablets are taken in 6 tablets divided into 2 to 3 times a day with water.
［実施例４］（顆粒剤の製造）
下記成分を混合して常法により顆粒剤（３０００ｍｇ）を製造した。
[Example 4] (Manufacture of granules)
Granules (3000 mg) were prepared by mixing the following ingredients in a conventional manner.
グルコサミン塩酸塩 １８００ｍｇ
プロテオグリカン ５ｍｇ
貝殻未焼成Ｃａ ２００ｍｇ
ショ糖脂肪酸エステル ５０ｍｇ
セレン ５ｍｇ
ビタミンＥ ５０ｍｇ
大麦若葉末 ８００ｍｇ
ナイアシン １０ｍｇ
ビオチン １０ｍｇ
プロリン ５ｍｇ
デンプン 残部
Glucosamine hydrochloride 1800mg
Proteoglycan 5mg
Seashell unfired Ca 200mg
Sucrose fatty acid ester 50mg
Selenium 5mg
Vitamin E 50mg
Barley grass powder 800mg
Niacin 10mg
Biotin 10mg
Proline 5mg
starch remainder
［実施例５］（インスタント粉末剤の製造）
下記成分を混合して常法によりインスタント粉末（６ｇ）を製造した。
[Example 5] (Production of instant powder)
An instant powder (6 g) was prepared by mixing the following ingredients in a conventional manner.
グルコサミン塩酸塩 ２５００ｍｇ
プロテオグリカン ５ｍｇ
貝殻未焼成Ｃａ ２００ｍｇ
大麦若葉末 １０００ｍｇ
長命草末 ５００ｍｇ
ショウガ末 ２５０ｍｇ
セレン ５ｍｇ
ビタミンＥ ３００ｍｇ
ビタミンＫ ２００ｍｇ
ナイアシン ５０ｍｇ
ビオチン ５０ｍｇ
プロリン ３０ｍｇ
バリン ３０ｍｇ
ロイシン ２０ｍｇ
イソロイシン ２０ｍｇ
アスパルテーム ３００ｍｇ
オリゴ糖 ５００ｍｇ
デキストリン 残部
Glucosamine hydrochloride 2500mg
Proteoglycan 5mg
Seashell unfired Ca 200mg
Barley grass powder 1000mg
Chomeisou end 500mg
Ginger powder 250mg
Selenium 5mg
Vitamin E 300mg
Vitamin K 200mg
Niacin 50mg
Biotin 50mg
Proline 30mg
Valine 30mg
Leucine 20mg
Isoleucine 20mg
Aspartame 300mg
Oligosaccharide 500mg
Dextrin remainder
［実施例６］（液剤の製造）
下記成分からなる液剤（５０ｍＬ）を製造した。
[Example 6] (Production of liquid agent)
A liquid preparation (50 mL) consisting of the following components was produced.
グルコサミン塩酸塩 ２０００ｍｇ
II型コラーゲン ２５ｍｇ
ミルクＣａ ２００ｍｇ
アスパルテーム ８００ｍｇ
赤ショウガ抽出物 ３００ｍｇ
ショウガ抽出物 ２００ｍｇ
葛花抽出物 １５０ｍｇ
プロリン １００ｍｇ
アスパラギン ５０ｍｇ
バリン ２５ｍｇ
ロイシン ２０ｍｇ
イソロイシン ２０ｍｇ
没食子酸 １０ｍｇ
ビタミンＣ ５ｍｇ
香料 適量
水 残部
Glucosamine hydrochloride 2000mg
Type II collagen 25mg
Milk Ca 200mg
Aspartame 800mg
Red ginger extract 300mg
Ginger extract 200mg
Kudzu flower extract 150mg
Proline 100mg
Asparagine 50mg
Valine 25mg
Leucine 20mg
Isoleucine 20mg
Gallic acid 10mg
Vitamin C 5mg
Fragrance (appropriate amount) Water (Remainder)
本発明の組成物は、高い関節機能改善効果を有し、経口剤又は外用剤として用いることができることから、本発明の産業上の有用性は高い。 The composition of the present invention has a high joint function improving effect and can be used as an oral preparation or an external preparation, and therefore the industrial utility of the present invention is high.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023184382A JP2023178487A (en) | 2020-07-28 | 2023-10-27 | Joint function improvement agent |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020127005A JP7071754B2 (en) | 2020-07-28 | 2020-07-28 | Joint function improving composition |
| JP2022072026A JP7382085B2 (en) | 2020-07-28 | 2022-04-26 | Joint function improvement composition |
| JP2023184382A JP2023178487A (en) | 2020-07-28 | 2023-10-27 | Joint function improvement agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072026A Division JP7382085B2 (en) | 2020-07-28 | 2022-04-26 | Joint function improvement composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023178487A true JP2023178487A (en) | 2023-12-14 |
| JP2023178487A5 JP2023178487A5 (en) | 2024-04-10 |
Family
ID=72830057
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127005A Active JP7071754B2 (en) | 2020-07-28 | 2020-07-28 | Joint function improving composition |
| JP2022072026A Active JP7382085B2 (en) | 2020-07-28 | 2022-04-26 | Joint function improvement composition |
| JP2023184382A Pending JP2023178487A (en) | 2020-07-28 | 2023-10-27 | Joint function improvement agent |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127005A Active JP7071754B2 (en) | 2020-07-28 | 2020-07-28 | Joint function improving composition |
| JP2022072026A Active JP7382085B2 (en) | 2020-07-28 | 2022-04-26 | Joint function improvement composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP7071754B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE212021000486U1 (en) | 2020-10-13 | 2023-10-02 | Nsk Ltd. | Screw shaft and electric steering wheel position adjustment device for a steering wheel |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9906808D0 (en) * | 1999-03-24 | 1999-05-19 | Kilgowan Limited | Formulation for treatment of pain |
| JP2001169752A (en) * | 1999-12-15 | 2001-06-26 | Fancl Corp | Food composition |
| JP2002154968A (en) | 2000-11-21 | 2002-05-28 | Noriyuki Oikawa | Composition for preventing or curing arthritis, or for improving symptom of arthritis |
| KR100420560B1 (en) * | 2001-03-10 | 2004-03-02 | 임시웅 | An arthritis and arthrosis injury prevention and treatment solution by synergistic action of glucose and amino acid |
| US20040241256A1 (en) * | 2002-12-05 | 2004-12-02 | Seymour Ehrenpreis | Medicinal compositions & therapeutic methods |
| WO2003049687A2 (en) * | 2001-12-06 | 2003-06-19 | Weller Health, Inc. | Medicinal compositions & therapeutic methods |
| JP4143387B2 (en) | 2002-11-21 | 2008-09-03 | 株式会社アセロラフーズ | healthy food |
| US8956677B2 (en) | 2005-11-23 | 2015-02-17 | The Coca-Cola Company | High-potency sweetener composition with glucosamine and compositions sweetened therewith |
| US8435588B2 (en) | 2005-11-23 | 2013-05-07 | The Coca-Cola Company | High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith |
| JP2007161688A (en) * | 2005-12-16 | 2007-06-28 | Hiroshima Univ | Chondrogenesis promoter |
| JP2008099562A (en) * | 2006-10-17 | 2008-05-01 | Kao Corp | Skin-beautifying oral composition |
| KR20090015616A (en) * | 2007-08-09 | 2009-02-12 | 세이모어 에렌프레이스 | Medicinal compositions and therapeutic methods for treating arthritis and other painful conditions |
| BR112012007598A2 (en) * | 2009-09-29 | 2016-08-23 | Shiseido Co Ltd | composition for the promotion of collagen production |
| WO2011040082A1 (en) * | 2009-09-30 | 2011-04-07 | 株式会社資生堂 | Laminin-332 production accelerating composition |
| JP5712393B2 (en) | 2010-10-12 | 2015-05-07 | ビーエイチエヌ株式会社 | Collagen absorption promoter and use thereof |
| JP5900815B2 (en) | 2011-06-20 | 2016-04-06 | 株式会社三協 | Arthritis improving composition |
| JP2014031323A (en) * | 2012-08-02 | 2014-02-20 | Shiseido Co Ltd | Composition for facilitating ceramide production |
| AU2014366768B2 (en) * | 2013-12-17 | 2017-10-12 | Simon Fraser University | Compounds, compositions and methods for attracting and/or arresting bed bugs |
-
2020
- 2020-07-28 JP JP2020127005A patent/JP7071754B2/en active Active
-
2022
- 2022-04-26 JP JP2022072026A patent/JP7382085B2/en active Active
-
2023
- 2023-10-27 JP JP2023184382A patent/JP2023178487A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020172548A (en) | 2020-10-22 |
| JP7071754B2 (en) | 2022-05-19 |
| JP2022095992A (en) | 2022-06-28 |
| JP7382085B2 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023178487A (en) | Joint function improvement agent | |
| JP2024009190A (en) | Bone fortifier dietary supplements | |
| JP5888574B1 (en) | Blood flow improver | |
| JP6584270B2 (en) | Blood flow improving composition | |
| JP5027361B2 (en) | Hyaluronic acid production promoter | |
| JP6742575B2 (en) | Joint function improving composition | |
| JP6744673B2 (en) | Joint function improving composition | |
| JP6841444B2 (en) | Immunostimulant | |
| JP2017088621A (en) | Hyperglycemia inhibiting composition | |
| JP2020186264A (en) | In-blood neutral fat increase inhibitory composition | |
| JP6608874B2 (en) | Beauty composition | |
| JP7090864B2 (en) | Composition | |
| JP2017002009A (en) | Adjuvant | |
| JP6838752B2 (en) | Blood flow improving composition | |
| JP6646369B2 (en) | Anti-fatigue agent | |
| JP2020094015A (en) | Hyaluronic acid production promoter, joint function improving agent, and oral composition | |
| JP6829487B2 (en) | Anti-fatigue | |
| JP2018009038A (en) | Oral composition | |
| JP6906248B2 (en) | Cosmetology composition | |
| JP6211558B2 (en) | Beauty composition | |
| JP2022173468A (en) | Bloodstream ameliorating composition | |
| JP2021050244A (en) | Anti-fatigue agent | |
| JP2024019607A (en) | beauty composition | |
| JP2022079610A (en) | Composition for suppressing increase in triglyceride in blood | |
| JP2022089939A (en) | Liver function improver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240401 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240401 |